Is Lansoprazole Safe?
Yes, lansoprazole is generally safe for most patients when used appropriately, though specific cautions apply when co-administered with clopidogrel in patients with acute coronary syndrome.
General Safety Profile
Lansoprazole has an established safety record across multiple populations. The FDA-approved labeling confirms its use for various indications including duodenal ulcers, gastric ulcers, GERD, and erosive esophagitis with well-characterized adverse event profiles 1.
Common Adverse Events
- Most frequent: Headache (7%), abdominal pain (5%), nausea (3%), and dizziness (3%) 2
- Pediatric populations: Constipation and headache are most common, with treatment-related adverse events occurring in 9-18% of children 3
- Overall discontinuation rate: Very low—in adolescent studies, only 1 patient discontinued due to adverse events (dizziness and vomiting) 2
Serious but Rare Adverse Events
One case report documents lansoprazole-induced bilateral asterixis (myoclonus) that resolved rapidly after discontinuation, demonstrating that while neurological dysfunction is possible, it appears exceedingly rare 4.
Critical Drug Interaction: Clopidogrel
The most clinically significant safety concern involves lansoprazole's interaction with clopidogrel in patients with acute coronary syndrome. Lansoprazole inhibits CYP450 2C19, the enzyme responsible for converting clopidogrel to its active metabolite 5, 6, 7.
Evidence of Pharmacodynamic Interaction
Studies demonstrate that lansoprazole reduces platelet inhibition when combined with clopidogrel. An open-label study showed that lansoprazole 30 mg daily reduced inhibition of platelet aggregation in patients taking clopidogrel 300 mg, while prasugrel's antiplatelet effect remained unaffected 6.
Clinical Outcomes: Mixed Evidence
The clinical significance remains controversial:
Concerning data: A Veterans Affairs retrospective cohort study (n=8,205) found concomitant lansoprazole and clopidogrel therapy associated with increased risk of death or rehospitalization for ACS 5, 6, 5.
Reassuring data: Multiple post-hoc analyses and the PRINCIPLE/TRITON-TIMI 38 trials showed that while PPIs (including lansoprazole) attenuated clopidogrel's pharmacodynamic effects, they did not affect clinical outcomes in patients receiving clopidogrel or prasugrel 6, 8.
FDA Guidance
The FDA advises healthcare providers to reevaluate the need for starting or continuing PPI treatment (including lansoprazole) in patients taking clopidogrel 7. Consider H2 blockers or antacids as alternatives, as these do not interfere with clopidogrel's antiplatelet activity 5, 9, 5.
Special Populations
Pregnancy
Lansoprazole appears safe during pregnancy. A prospective Japanese cohort study (106 exposed pregnancies) found no increased risk of major malformations: 1.0% in lansoprazole group versus 1.9% in controls (adjusted OR: 0.51,95% CI: 0.07-3.79) 10. Meta-analysis of 1,530 PPI-exposed pregnancies showed no significant increase in congenital malformations (OR=1.12,95% CI 0.86-1.45) or spontaneous abortion 1.
Lactation
No data exist on lansoprazole presence in human milk, though it appears in rat milk. The decision to breastfeed should weigh maternal clinical need against potential infant risks 1.
Pediatric Use
Ages 1-17 years: Safety and effectiveness established for symptomatic GERD and erosive esophagitis. Weight-based dosing (15 mg for ≤30 kg; 30 mg for >30 kg) for up to 12 weeks is well-tolerated 1, 2, 3.
Under 1 year: Not recommended—lansoprazole was ineffective in infants 1-12 months with symptomatic GERD in controlled trials 1.
Important pediatric caveat: Juvenile rat studies showed heart valve thickening and bone changes at high doses. Do not exceed recommended doses or duration in children 1.
Hepatic Impairment
Reduce dose to 15 mg daily in severe liver impairment (Child-Pugh C) 1.
Long-Term Safety
Lansoprazole has been used continuously for over 4 years in Zollinger-Ellison syndrome patients without major safety concerns 1. A 12-month study in NSAID users showed acceptable safety profile, with diarrhea as the most frequent adverse event 11.
Gastrin Elevation
Mean fasting serum gastrin increases significantly during treatment (from 58.0 pg/mL to 121.9 pg/mL), though median values remain within normal range (25-111 pg/mL) 3. This is an expected pharmacologic effect of acid suppression.
Clinical Pitfalls to Avoid
- Do not combine with clopidogrel in ACS patients without careful risk-benefit assessment; strongly consider H2 blockers instead
- Do not use in infants <1 year—proven ineffective
- Do not exceed recommended pediatric dosing or duration due to potential bone and cardiac effects
- Reduce dose in severe hepatic impairment
- Take before meals for optimal efficacy 1